An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources

BMC Medical Informatics and Decision Making - 2021
Hyunah Shin1, Suehyun Lee1
1Health Care Data Science Center, Konyang University Hospital, 158 Gwanjeo-dong-ro, Seo-gu, Daejeon, Republic of Korea

Tóm tắt

Abstract Background Adverse drug reactions (ADRs) are regarded as a major cause of death and a major contributor to public health costs. For the active surveillance of drug safety, the use of real-world data and real-world evidence as part of the overall pharmacovigilance process is important. In this regard, many studies apply the data-driven approaches to support pharmacovigilance. We developed a pharmacovigilance data-processing pipeline (PDP) that utilized electronic health records (EHR) and spontaneous reporting system (SRS) data to explore pharmacovigilance signals. Methods To this end, we integrated two medical data sources: Konyang University Hospital (KYUH) EHR and the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). As part of the presented PDP, we converted EHR data on the Observation Medical Outcomes Partnership (OMOP) data model. To evaluate the ability of using the proposed PDP for pharmacovigilance purposes, we performed a statistical validation using drugs that induce ear disorders. Results To validate the presented PDP, we extracted six drugs from the EHR that were significantly involved in ADRs causing ear disorders: nortriptyline, (hazard ratio [HR] 8.06, 95% CI 2.41–26.91); metoclopramide (HR 3.35, 95% CI 3.01–3.74); doxycycline (HR 1.73, 95% CI 1.14–2.62); digoxin (HR 1.60, 95% CI 1.08–2.38); acetaminophen (HR 1.59, 95% CI 1.47–1.72); and sucralfate (HR 1.21, 95% CI 1.06–1.38). In FAERS, the strongest associations were found for nortriptyline (reporting odds ratio [ROR] 1.94, 95% CI 1.73–2.16), sucralfate (ROR 1.22, 95% CI 1.01–1.45), doxycycline (ROR 1.30, 95% CI 1.20–1.40), and hydroxyzine (ROR 1.17, 95% CI 1.06–1.29). We confirmed the results in a meta-analysis using random and fixed models for doxycycline, hydroxyzine, metoclopramide, nortriptyline, and sucralfate. Conclusions The proposed PDP could support active surveillance and the strengthening of potential ADR signals via real-world data sources. In addition, the PDP was able to generate real-world evidence for drug safety.

Từ khóa


Tài liệu tham khảo

Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Intern Med. 2003;18:57–60. https://doi.org/10.1046/j.1525-1497.2003.20130.x.

Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med. 2008;358:637–9. https://doi.org/10.1056/nejme0708842.

Naidu MVS, Sushma DS, Jaiswal V, Asha S, Pal T. The role of advanced technologies supplemented with traditional methods in pharmacovigilance sciences. Recent Patents Biotechnol. 2020;14. https://doi.org/https://doi.org/10.2174/1872208314666201021162704.

McNeil JJ, Piccenna L, Ronaldson K, Ioannides-Demos LL. The value of patient-centred registries in phase IV drug surveillance. Pharmaceut Med. 2010;24:281–8. https://doi.org/10.1007/bf03256826.

Kim H-S, Kim JH. Proceed with caution when using real world data and real world evidence. J Korean Med Sci. 2019;34. https://doi.org/https://doi.org/10.3346/jkms.2019.34.e28.

Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2012;20:413–9. https://doi.org/10.1136/amiajnl-2012-000930.

Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, Suissa S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol Drug Saf. 2019;29:3–7. https://doi.org/10.1002/pds.4722.

Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54–60. https://doi.org/10.1136/amiajnl-2011-000376.

Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, et al. A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 2015;38:749–65. https://doi.org/10.1007/s40264-015-0297-5.

Rho MJ, Kim SR, Park SH, Jang KS, Park BJ, Choi IY. Development common data model for adverse drug signal detection based on multi-center EMR systems. In: 2013 International conference on information science and applications (ICISA). IEEE; 2013. https://doi.org/https://doi.org/10.1109/icisa.2013.6579355.

Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36:119–34. https://doi.org/10.1007/s40264-012-0009-3.

Rho MJ, Kim SR, Park SH, Jang KS, Park BJ, Hong JY, et al. Common data model for decision support system of adverse drug reaction to extract knowledge from multi-center database. Inf Technol Manage. 2015;17:57–66. https://doi.org/10.1007/s10799-015-0240-6.

Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602. https://doi.org/10.1016/s0140-6736(16)31678-6.

World Health Organization, et al. Global costs of unaddressed hearing loss and cost-effectiveness of interventions: a WHO report, 2017. World Health Organization. 2017.

Shariff M. Analysis of hearing loss by pure tone audiometry in patients with chronic suppurative otitis media. Natl J Physiol Pharm Pharmacol. 2019;:1. https://doi.org/https://doi.org/10.5455/njppp.2019.9.0308223032019.

Chow AHC, Cai T, McPherson B, Yang F. Otitis media with effusion in children: cross-frequency correlation in pure tone audiometry. PLoS ONE. 2019;14:e0221405. https://doi.org/10.1371/journal.pone.0221405.

Oosterloo BC, Homans NC, Baatenburg de Jong RJ, Ikram MA, Nagtegaal AP, Goedegebure A. Assessing hearing loss in older adults with a single question and person characteristics; Comparison with pure tone audiometry in the Rotterdam Study. PLOS ONE. 2020;15:e0228349. https://doi.org/https://doi.org/10.1371/journal.pone.0228349.

Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, et al. ADEpedia-on-OHDSI: a next generation pharmacovigilance signal detection platform using the OHDSI common data model. J Biomed Inform. 2019;91:103119. https://doi.org/10.1016/j.jbi.2019.103119.

Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796–803. https://doi.org/10.7150/ijms.6048.

Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3. https://doi.org/https://doi.org/10.1038/sdata.2016.26.

Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2015;14:248–54. https://doi.org/10.1016/j.jcf.2014.07.009.

Lee S, Choi J, Kim H-S, Kim GJ, Lee KH, Park CH, et al. Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records. J Am Med Inform Assoc. 2017;24:697–708. https://doi.org/10.1093/jamia/ocw168.

Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med. 2003;163:2716. https://doi.org/10.1001/archinte.163.22.2716.

Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, et al. Potentially inappropriate medication use in the community-dwelling elderly. JAMA. 2001;286:2823. https://doi.org/10.1001/jama.286.22.2823.

ICH E. Clinical investigation of medicinal products in the paediatric population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). London, 2000;

Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 6th ed. Hudson, OH: LexiComp, Inc; 1999.

Kliegman RM., et al. Nelson textbook of pediatrics e-book. Elsevier Health Sciences, 2007.

United Nations Department of Economic and Social Affairs. Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments. [https://www.un.org/esa/coordination/CL-14-Final.for.Printing.pdf].

Ninan B, Wertheimer AI. Withdrawing drugs in the US versus other countries. 2012.

Bisht M, Bist SS. Ototoxicity: the hidden menace. Indian J Otolaryngol Head Neck Surg. 2011;63:255–9. https://doi.org/10.1007/s12070-011-0151-8.

van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10. https://doi.org/10.1002/pds.668.

Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. Hear Res. 2007;226:221–31. https://doi.org/10.1016/j.heares.2006.08.004.

Kontopantelis E, Reeves D. Metaan: random-effects meta-analysis. Stata J: Promoting Commun Stat Stata. 2010;10:395–407. https://doi.org/10.1177/1536867x1001000307.

Sullivan MD, Sakai CS, Dobie RA, Katon WJ. Treatment of depressed tinnitus patients with nortriptyline. Ann Otol Rhinol Laryngol. 1989;98:867–72. https://doi.org/10.1177/000348948909801107.

Sullivan M. A randomized trial of nortriptyline for severe chronic tinnitus. Arch Intern Med. 1993;153:2251. https://doi.org/10.1001/archinte.1993.00410190091011.

Baldo P, Doree C, Molin P, McFerran D, Cecco S. Antidepressants for patients with tinnitus. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.cd003853.pub3.

Tinnitus: http://www.health.kr/Menu.PharmReview/View.asp?PharmReview_IDX=2800

Zhang X, Duan R, Du J, Huang J, Chen Y, Tao C. Comparing pharmacovigilance outcomes between FAERS and EMR data for acute mania patients. In: 2018 IEEE international conference on healthcare informatics workshop (ICHI-W). IEEE; 2018. https://doi.org/https://doi.org/10.1109/ichi-w.2018.00018.

Thông tin
Thông tin xuất bản

BMC Medical Informatics and Decision Making

Thông tin tác giả